Zantac Lawsuit Status: What the Court Record Actually Shows
GSK agreed to pay up to $2.2 billion, yet no jury has ever found that Zantac caused a plaintiff's cancer. The federal MDL is down to 847 of 15,018 cases and Delaware just shifted in the manufacturers' favour. Here is the honest picture.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
The Allegation and the Science Fight
Plaintiffs allege that ranitidine — sold as Zantac — can break down into NDMA, a probable human carcinogen, particularly under heat or extended storage, and that the manufacturers knew or should have known. The FDA requested market withdrawal of all ranitidine products in April 2020.
Everything in this litigation turns on whether plaintiffs can prove general causation with expert testimony. That is where they have repeatedly lost, and it is why the headline settlement figures and the courtroom record point in such different directions.
Case Details
Federal: In re Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924 (S.D. Fla., Judge Robin Rosenberg). In December 2022 the court excluded all of the plaintiffs' general-causation experts and granted summary judgment on five designated cancers — bladder, esophageal, gastric, liver and pancreatic. An appeal was argued before the Eleventh Circuit on October 10, 2025; as of early August 2026, roughly ten months later, no decision has issued. State court: Delaware carried close to 75,000 filings.
Where It Stands in August 2026
Delaware moved toward the manufacturers. In July 2025 the Delaware Supreme Court reversed a lower court that had applied a permissive standard to expert testimony under Delaware Rule of Evidence 702. That lower ruling had let essentially all of the plaintiffs' experts through; the reversal removed that footing for tens of thousands of Delaware filings.
No plaintiff has ever won a jury verdict. The first trial, in Cook County, Illinois in May 2024, ended in a defence verdict for GSK and Boehringer Ingelheim. Subsequent trials produced defence verdicts or mistrials. That record matters more than any settlement headline when judging what a new case is worth.
Who Settled, and For How Much
The settlements and the verdicts tell opposite stories, so it is worth separating them carefully.
GSK — up to $2.2 billion, announced October 9, 2024, resolving roughly 80,000 cases and about 93 percent of its state-court docket across ten plaintiffs' firms. Separately GSK paid $70 million to resolve a whistleblower qui tam action brought by Valisure. This is the only manufacturer with a publicly quantified global programme.
Sanofi — $200 to $250 million (May 2024), covering more than 10,000 claims.
Pfizer has settled more than 10,000 cases but has never published a total. Boehringer Ingelheim has no global settlement and continues to litigate, resolving individual cases confidentially.
Treating all four as "the manufacturers settled" would be wrong: only GSK has a figure, and settling to end litigation is not an admission that the drug caused anyone's cancer.
What a Case Is Realistically Worth Now
Statutes of limitation are also state-specific, generally two to four years from diagnosis with genuine variation from one to six years. That is real legal diversity, not uncertainty in this summary — it means the answer depends entirely on where you live and when you were diagnosed.
Timeline
- 1
April 2020 — FDA requests withdrawal
The FDA asks manufacturers to remove all ranitidine products from the market over NDMA concerns, triggering the litigation wave.
- 2
December 2022 — the ruling that shaped everything
Judge Rosenberg excludes all plaintiff general-causation experts and grants summary judgment on five designated cancers. The federal MDL never recovers from this.
- 3
May 2024 — first jury trial, defence verdict
A Cook County, Illinois jury finds for GSK and Boehringer Ingelheim. Later trials produce defence verdicts or mistrials.
- 4
October 9, 2024 — GSK settles up to $2.2 billion
About 80,000 cases and 93 percent of GSK's state-court docket, plus $70 million to resolve a separate whistleblower action.
- 5
July 2025 — Delaware Supreme Court reverses
The court rejects the permissive expert standard the trial court had applied, removing the basis on which roughly 75,000 Delaware cases had been allowed to proceed.
- 6
October 10, 2025 to today — Eleventh Circuit silent
The federal appeal is argued. Ten months later no decision has issued. Meanwhile the MDL stands at 847 of 15,018 cases.
What to Be Careful About
Mass tort advertising for this drug has continued well past the point where the underlying cases got hard. That gap is where the risk sits.
Advertising that presents causation as settled
Marketing pages describe Zantac as a 2026 opportunity. The court record says the opposite: experts excluded federally, Delaware reversed, no plaintiff jury verdict anywhere. An ad is not a legal assessment.
Treating the $2.2 billion as a fund you can claim from
It is not a claims-administered settlement with a form and a deadline. It resolved specific inventories of already-filed cases through the firms that represented them. There is no public claim portal.
Any promise of a specific payout
Given the causation rulings, no honest source can quote you a figure for a new case. A specific dollar promise is a marketing device.
Frequently Asked Questions
Is the Zantac litigation over?
Not formally. 847 federal cases remain pending and the Eleventh Circuit appeal is undecided. But 94 percent of the federal docket is gone, Delaware has shifted toward the manufacturers, and no jury has found for a plaintiff. On the federal side it is winding down rather than building.
Can I still file a claim?
Filing a lawsuit is different from claiming in a settlement, and this is a lawsuit situation — there is no claim form or administrator. Whether you can still file depends on your state's statute of limitations, generally two to four years from diagnosis. Given the causation rulings, an honest lawyer will tell you it is a difficult case.
GSK paid $2.2 billion. Does that mean Zantac causes cancer?
No. Settlements resolve litigation risk and cost; they are not findings of fact. The only juries to consider the question have found for the defence. Both things are true at once, and holding them together is the accurate picture.
Why did the experts get excluded?
In December 2022 the MDL court applied the federal standard for expert admissibility and found the plaintiffs' general-causation opinions did not meet it, then granted summary judgment on five cancers. Without admissible general causation, a product liability case cannot reach a jury.
What about the other manufacturers?
Sanofi settled $200 to $250 million for more than 10,000 claims in May 2024. Pfizer has settled more than 10,000 cases without publishing a total. Boehringer Ingelheim has no global settlement and continues to defend.
Are law firms still taking Zantac cases?
Some are and advertise heavily; many stopped active recruitment after the 2022 exclusion ruling. Litigation-support analysts describe a split. If a firm is enthusiastic about your case, it is fair to ask directly how they intend to prove causation given the rulings.
How long do I have?
It depends on your state and typically runs from diagnosis, generally two to four years with real variation from one to six. Because the clock usually starts at diagnosis rather than at use of the drug, older use does not automatically mean the deadline has passed.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.